DMK Pharmaceuticals Profit Margin

DMK Pharmaceuticals (DMK) currently reports a profit margin of -5.57% as of December 2022. That compares with -20.75% in the prior-year period — up 73.2% year over year. That is below the Healthcare sector average of 15.52%. Use the charts on this page to explore DMK Pharmaceuticals's profit margin history and peer comparisons.

DMK Pharmaceuticals's profit margin increased from -20.75% to -5.57% — a 73.2% year-over-year increase (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

DMK Pharmaceuticals's profit margin of -5.57% is lower than the Healthcare sector average of 15.52%. That is roughly 3687.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but DMK Pharmaceuticals's current -5.57% should be judged against Healthcare norms (sector average: 15.52%) and against DMK's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -5.57%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.52%. From there, open related valuation or income-statement pages for DMK Pharmaceuticals, and consider following DMK for alerts when major investors trade the stock.